GC Biopharma Corp.: Influenza, Human trials

The registry lists 15 Influenza, Human studies with GC Biopharma Corp. as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 5Phase 3 9Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or OlderNot yet recruitingNCT07883928Phase 2/3
• A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy SubjectsCompletedNCT03657719Phase 2
• A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy AdultsCompletedNCT03357263Phase 1
• A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of AgeStatus unknownNCT03285997Phase 3
• A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and OlderCompletedNCT02917304Phase 3
• A Study to Evaluate Efficacy and Safety of GC3110B in Healthy AdultsStatus unknownNCT02915809Phase 3
• A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III StudyStatus unknownNCT02658409Phase 3
• A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy ChildrenCompletedNCT02541253Phase 3
• A Multicenter, Double-blind, Parallel Phase III StudyCompletedNCT02352584Phase 3
• Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)CompletedNCT02249221Phase 1/2
• A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)CompletedNCT02121782Phase 1/2
• Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.CompletedNCT02067117Phase 4
• Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersCompletedNCT01987011Phase 3
• Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult VolunteersCompletedNCT01389466Phase 1/2
• A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) VaccineCompletedNCT01201902Phase 3